GeoVax Labs presents Gedeptin clinical data at the AACR-AHNS

GeoVax Labs announced the presentation of Phase 1/2 clinical trial data for GeoVax’s gene therapy candidate, Gedeptin at the American Association for Cancer Research, AACR, and the American Head and Neck Society, AHNS, joint Head and Neck Cancer Conference in Montreal, QC, Canada. The presentation, titled “Phase 1/ 2 study of Ad/PNP with fludarabine for the treatment of head neck squamous cell carcinoma”, describes the evaluation of Gedeptin as an experimental therapy for refractory solid tumors. The ongoing Phase 1/2 trial is evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma, with tumor(s) accessible for injection and no curable treatment options. The poster presentation, highlighted the following data: 8 patients have been enrolled in the study to date. No dose limiting toxicities or serious adverse events are definitively attributable to treatment. Additionally, no adverse events above grade 3 severity have been reported. Up to 5 cycles of Gedeptin treatment have been administered without limiting sequelae. Intratumoral expression of the PNP transgene by RT-PCR has been established in treated tumors studied to date. Impairment of tumor growth in targeted lesions was seen in 5 of 7 patients; tumor response assessment in one patient remains under study.